Effects of cyclopiazonic acid, a novel Ca(2+)-ATPase inhibitor, on contractile responses in skinned ileal smooth muscle.
1. Effects of cyclopiazonic acid (CPA), a specific inhibitor of the Ca(2+)-ATPase in sarcoplasmic reticulum (SR) of skeletal and cardiac muscles, on contractile responses induced by Ca(2+)-release from intracellular storage sites were examined in the longitudinal smooth muscle strip of the guinea-pig ileum skinned with beta-escin. 2. Ca(2+)-loading of storage sites (Ca(2+)-uptake) was performed in pCa 6.3 solution. The amount of Ca2+ taken up was monitored by use of the amplitude of contraction following application of 25 mM caffeine or 25 microM inositol 1,4,5-trisphosphate (IP3). 3. Contractile responses to caffeine or IP3 were reduced or abolished when the preceding Ca(2+)-uptake was performed in the presence of 0.1-10 microM CPA. The dose of CPA required to inhibit the contraction induced by caffeine or IP3 by 50% was approximately 0.6 microM. The CPA-sensitive Ca(2+)-uptake completely depended upon the presence of ATP in the solution during Ca(2+)-uptake. 4. When 1 microM CPA was added after Ca(2+)-uptake, the subsequent caffeine- or IP3-induced contraction was not significantly affected by the presence of CPA. 5. Acetylcholine-induced contraction was also almost abolished when the preceding Ca(2+)-uptake was performed in the presence of 10 microM CPA. 6. The relationship between pCa and contraction was not affected by the presence of 10 microM CPA in skinned fibres where Ca2+ storage sites had been destroyed by treatment with A23187. The enhancement of contraction in pCa 6.0 solution by calmodulin was not affected by 10 microM CPA.7. These results suggest that CPA selectively inhibits ATP-dependent Ca2"-uptake into intracellular storage sites in skinned ileal smooth muscle strips. CPA appears to be a potent, reversible, and very specific inhibitor of the Ca2+-pump in the storage sites of smooth muscle, and is an extremely valuable pharmacological tool.
Uyama
Y
Y
Department of Chemical Pharmacology, Faculty of Pharmaceutical Sciences, Nagoya City University, Japan.
Imaizumi
Y
Y
Watanabe
M
M
D000109:Acetylcholine / Q000494:pharmacology; D000818:Animals; D002110:Caffeine / Q000494:pharmacology; D002118:Calcium / Q000378:metabolism; D000252:Calcium-Transporting ATPases / Q000037:antagonists & inhibitors*; D004928:Escin / Q000494:pharmacology; D006168:Guinea Pigs; D007082:Ileum / Q000187:drug effects* / Q000378:metabolism / Q000502:physiology; D007211:Indoles / Q000494:pharmacology*; D015544:Inositol 1,4,5-Trisphosphate / Q000494:pharmacology; D008297:Male; D009119:Muscle Contraction / Q000187:drug effects*; D009130:Muscle, Smooth / Q000187:drug effects* / Q000378:metabolism / Q000502:physiology; D012519:Sarcoplasmic Reticulum / Q000187:drug effects
D007211:Indoles; D002110:Caffeine; D004928:Escin; D015544:Inositol 1,4,5-Trisphosphate; D000252:Calcium-Transporting ATPases; D000109:Acetylcholine; D002118:Calcium; C000543:cyclopiazonic acid